Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment
Daniel R A Cox,
William Chung,
Josephine Grace,
Darren Wong,
Numan Kutaiba,
Dinesh Ranatunga,
Richard Khor,
Marcos V Perini,
Michael Fink,
Robert Jones,
Mark Goodwin,
Alex Dobrovic,
Adam Testro,
Vijayaragavan Muralidharan
Affiliations
Daniel R A Cox
Department of Surgery (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
William Chung
Department of Medicine (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
Josephine Grace
Department of Medicine (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
Darren Wong
Department of Medicine (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
Numan Kutaiba
Department of Radiology Austin Health Melbourne Victoria Australia
Dinesh Ranatunga
Department of Radiology Austin Health Melbourne Victoria Australia
Richard Khor
Department of Radiation Oncology Austin Health Melbourne Victoria Australia
Marcos V Perini
Department of Surgery (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
Michael Fink
Department of Surgery (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
Robert Jones
Department of Surgery (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
Mark Goodwin
Department of Radiology Austin Health Melbourne Victoria Australia
Alex Dobrovic
Department of Surgery (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
Adam Testro
Department of Medicine (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
Vijayaragavan Muralidharan
Department of Surgery (Austin Precinct) The University of Melbourne Melbourne Victoria Australia
Abstract Hepatocellular carcinoma (HCC) is an aggressive primary malignancy of the liver and is the third most common cause of cancer‐related global mortality. There has been a steady increase in treatment options for HCC in recent years, including innovations in both curative and non‐curative therapies. These advances have brought new challenges and necessary improvements in strategies of disease monitoring, to allow early detection of HCC recurrence. Current serological and radiological strategies for post‐treatment monitoring and prognostication and their limitations will be discussed and evaluated in this review.
